PEPTONIC Medical AB: Peptonic Medical AB announces outcome of the rights issue

Final outcome

The subscription period in the Rights Issue ended on 28 January 2026. The outcome shows that 48,577,918 units were subscribed for with the support of unit rights, corresponding to approximately 52.0 per cent of the Rights Issue. In addition, 472,387 units were subscribed for without the support of unit rights, corresponding to approximately 0.5 per cent of the Rights Issue. In total, 49,050,305 units were subscribed for, consisting of 4,905,030,500 shares and 4,905,030,500 warrants of series TO6 issued free of charge, corresponding to approximately 52.5 per cent of the Rights Issue. Each unit consists of one hundred (100) shares and one hundred (100) warrants of series TO6 issued free of charge. As a result, guarantee commitments of 13,568,880 units, corresponding to approximately 14.5 per cent of the Rights Issue, will be utilised.

The Rights Issue will result in proceeds to the Company of approximately SEK 10.0 million before issue costs. Upon full exercise of all warrants of series TO6 issued in the Rights Issue, and assuming a subscription price per share of SEK 0.0016, corresponding to the subscription price per share in the Rights Issue, the Company may receive an additional maximum amount of approximately SEK 10.0 million before issue costs.

Resolution on directed set-off issue

Within the framework of the reconstruction carried out by the Company during 2025, it was resolved, in addition to the resolution on the Rights Issue, that the Company would carry out a directed set-off issue to a number of creditors for set-off of claims against the Company (the "Directed Set-off Issue"). The Directed Set-off Issue comprised 50,246,819 units, each unit containing one hundred (100) shares and one hundred (100) warrants of series TO6. The subscription price per unit amounted to SEK 0.16, corresponding to SEK 0.0016 per share. The warrants of series TO6 were issued free of charge.

Allocation of units subscribed for without the support of unit rights

Allocation of units subscribed for without the support of unit rights has been carried out in accordance with the principles set out in the EU Growth Prospectus published by the Company on 13 January 2026 in connection with the Rights Issue. Nominee-registered shareholders will receive notification of allocation in accordance with instructions from their respective nominees.

Trading in paid subscribed units ("BTU")

Trading in BTU will take place until conversion of BTU into shares and warrants of series TO6. This will occur after the Rights Issue has been registered with the Swedish Companies Registration Office (Bolagsverket), which is expected to take place during week 7, 2026.

Shares, share capital, and dilution

Through the Rights Issue, the number of shares will increase by 6,261,918,500 shares. Furthermore, through the Directed Set-off Issue, the number of shares in the Company will increase by 5,024,681,900 shares. In total, the number of shares in the Company will thus increase by 11,286,600,400 shares, from 9,337,409,114 shares to 20,624,009,514 shares, corresponding to a dilution of approximately 54.7 per cent of the total number of shares and votes in the Company for existing shareholders who have not participated in the Rights Issue or the Directed Set-off Issue. The share capital will increase by a total of 1,128,660.04 SEK, from SEK 933,740.91 to 2,062,400.95 SEK. In the event that all warrants of series TO6 issued within the framework of the Rights Issue and the Directed Set-off Issue are exercised, the number of shares in the Company will increase by an additional 11,286,600,400 shares, from 20,624,009,514 shares to 31,910,609,914 shares, corresponding to a further dilution of approximately 35.4 per cent of the total number of shares and votes in the Company. Furthermore, the share capital will increase by an additional 1,128,660.04 SEK, from 2,062,400.95 SEK to 3,191,060.99 SEK.

Warrants of series TO6

• Each warrant of series TO6 entitles the holder to subscribe for one (1) new share in the Company.
• The subscription price for subscription of shares with support of warrants of series TO6 amounts to seventy (70) per cent of the volume-weighted average price of the Company's share during the period from and including 18 May 2026 up to and including 29 May 2026, however not lower than the quota value of the share corresponding to SEK 0.0001.
• Warrants of series TO6 may be exercised for subscription of new shares during the period from and including 1 June 2026 up to and including 12 June 2026.
• Upon full exercise of all warrants of series TO6 issued within the framework of the Rights Issue and the Directed Set-off Issue, and assuming a subscription price of SEK 0.0016, the Company may receive an additional maximum amount of approximately SEK 18.1 million.
• The warrants of series TO6 are intended to be admitted to trading on Spotlight Stock Market as soon as possible after registration with the Swedish Companies Registration Office.

For more information contact:

Anna Linton, CEO Peptonic Medical AB

Email: anna.linton@peptonicmedical.se

Phone: +46 70-244 92 07

About Peptonic Medical AB

Peptonic Medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, the United States, Belarus, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release contains certain forward-looking information that reflects the Company's present view of future events as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development, and actual outcomes may differ materially from the statements set forth in the forward-looking information.